General Medical Devices

Olympus Corp.

Olympus Announces Investment of Additional $150 Million in Venture Fund

Olympus Signs International Distribution Agreement for GORE® VIABIL® Biliary Stents with W. L. Gore & Associates

Olympus Launches VISERA™ S OTV-S500 Imaging Platform

Olympus Launches EU-ME3 Ultrasound Processor

Olympus Launches ScopeLocker Air Endoscope Dryer

Olympus Launches EVIS X1™ Endoscope System

Olympus ESD Receives AMA CPT Code Support

Olympus to Showcase Endoscopic Technologies at DDW

FactSet: Olympus Average Rating is Outperform

Changes in the domestic endoscope market

7733

Olympus Corporation has announced an additional $150 million investment in its corporate venture capital fund, Olympus Innovation Ventures, LLC, with the launch of Olympus Innovation Ventures Fund II. This fund will focus on MedTech startups in Gastrointestinal, Urology, and Respiratory fields. The initiative aims to generate M&A opportunities, partnerships, and market insights. Cerity Partners Ventures will continue to manage the fund. Olympus aims to strengthen its MedTech leadership through innovation and strategic investments.

Japan Corporate News

Olympus Triples Venture Capital Fund Investment to Strengthen MedTech Leadership

Dec 15 (Reuters) - Olympus Corp (7733.T) :* OLYMPUS CORP - NOTICE REGARDING ADDITIONAL INVESTMENT IN CORPORATE VENTURE CAPITAL FUND "OLYMPUS INNOVATION VENTURES FUND II" Source text: Further company coverage: (7733.T)

Reuters

Olympus Corp - Notice Regarding Additional Investment In Corporate Venture Capital Fund "Olympus Innovation Ventures Fund Ii"

Today, in Center Valley, Pennsylvania, Olympus Corporation disclosed a voluntary medical device corrective action on Dec. 5, 2025, concerning its Single-Use Ligating Device known as "PolyLoop" due to safety concerns. The PolyLoop device is typically used with Olympus equipment.

Unusual Whales

Olympus issues a voluntary corrective action for its Single-Use Ligating Device ("PolyLoop") due to safety concerns.

Olympus Corporation has announced a voluntary corrective action for its Single-Use Ligating Device, "PolyLoop," due to potential safety issues. The device may fail to release as expected, posing risks such as bleeding and mucosal injury. Customers were notified in November 2025 and are advised to follow updated guidance and report any issues to the FDA's MedWatch program. No deaths have been reported.

prnewswire

16:01 ET
			
			
				Olympus Announces Voluntary Corrective Action for the Single-Use Ligating Device

CNMD

Olympus, Gore, and ConMed announced the transition of commercial support for the GORE® VIABIL® Biliary Endoprosthesis in the U.S. Effective January 1, 2026, Olympus will take over distribution, while ConMed will support the product until December 31, 2025. The transition aims to ensure continued access to the device for patients and healthcare providers.

Conmed

08:00 ET
			
			
				Olympus, Gore, and ConMed Announce Transition of Commercial Support for the GORE® VIABIL® Biliary Endoprosthesis in the United States

NVDA

SFTBY

9984

Japan's Nikkei 225 Index fell 2.3% to 48,678.11, led by declines in technology stocks following Wall Street's drop. The Topix index also decreased by 0.6%. Major AI sector stocks like Advantest and SoftBank Group saw significant losses, with Advantest down 9.3% and SoftBank over 10%. The decline was influenced by valuation concerns affecting U.S. stocks, particularly Nvidia.

- Japan’s Nikkei share average fell 2.3% to 48,678.11, influenced by declines in technology stocks amid U.S. market valuation concerns.  
- The broader Topix index decreased by 0.6%, with 131 stocks advancing and 93 declining.  
- Major losses were seen in the AI sector, particularly Advantest, which dropped 9.3%, and SoftBank Group, which fell over 10%.

NVIDIA

SoftBank

SoftBank Group Corp.

Pro Ultrshrt Yen

Japan's Nikkei slumps as tech shares track Wall Street declines

Olympus Shares Jump Most in Six Years on Job Cuts, Overhaul Plan

marketscreener

Olympus Shares Jump Most in Six Years on Job Cuts, Overhaul Plan

Olympus Corp. (OLYMY) reported a decline in Q2 earnings, with revenue falling 4.2% to ¥454,350 million and operating profit down 34.6% to ¥46,133 million for the six months ending September 30, 2025. The Gastrointestinal Solutions Division saw a 4.8% revenue drop, while the Surgical & Interventional Solutions Division decreased by 2.7%. Profit attributable to owners fell 40.4% to ¥29,187 million. Despite challenges from U.S. tariffs and competition, Olympus is investing in strategic initiatives, including a joint venture for endoluminal robots, and remains optimistic about future performance.

Tip Ranks

Olympus Corp. Reports Decline in Earnings Amid Market Challenges

Nov 7 (Reuters) -* JAPAN’S OLYMPUS TO REDUCE HEADCOUNT BY 2,000 IN GLOBAL OVERHAUL - BLOOMBERG NEWS Source text: Further company coverage: (7733.T)

Japan's Olympus To Reduce Headcount By 2,000 In Global Overhaul - Bloomberg News

From October 1, 2025 to October 31, 2025, the company has repurchased 6,864,400 shares, representing 0.61% for ¥12,964.95 million. With this, the company has completed the repurchase of 27,630,600 shares, representing 2.45% for ¥49,999.91 million under the buyback announced on May 13, 2025.

Olympus Triples Venture Capital Fund Investment to Strengthen MedTech Leadership

Olympus Corp - Notice Regarding Additional Investment In Corporate Venture Capital Fund "Olympus Innovation Ventures Fund Ii"

Olympus issues a voluntary corrective action for its Single-Use Ligating Device ("PolyLoop") due to safety concerns.

16:01 ET Olympus Announces Voluntary Corrective Action for the Single-Use Ligating Device

08:00 ET Olympus, Gore, and ConMed Announce Transition of Commercial Support for the GORE® VIABIL® Biliary Endoprosthesis in the United States